
|Articles|July 1, 2004
Genaera begins more squalamine trials
Genaera Corp. will begin three phase II trials on squalamine, its systemically administered anti-angiogenic drug.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
2
EURETINA 2026: Eyestem interim Phase 2 results for clinical study of Eyecyte-RPE for GA secondary to dry AMD
3
EURETINA 2026: Real-world evidence on retinal biosimilars
4
EURETINA 2026: 3 gene therapy programmes for nAMD approaching phase 3 readouts
5














